F Caligaris-Cappio
Overview
Explore the profile of F Caligaris-Cappio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
110
Citations
2295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown J, Hillmen P, OBrien S, Barrientos J, Reddy N, Coutre S, et al.
Leukemia
. 2017 Jun;
32(1):83-91.
PMID: 28592889
In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic...
2.
Galletti G, Caligaris-Cappio F, Bertilaccio M
Leukemia
. 2016 Sep;
30(12):2293-2301.
PMID: 27677742
The development and progression of chronic B-cell tumors depend on a complex microenvironmental network of cells that include monocyte-derived macrophages. In chronic lymphocytic leukemia (CLL) the survival of malignant cells...
3.
Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, et al.
Ann Oncol
. 2012 Nov;
24(3):561-76.
PMID: 23175624
To complete the existing treatment guidelines for all tumor types, ESMO organizes consensus conferences to better clarify open issues in each disease. In this setting, a consensus conference on the...
4.
Bertilaccio M, Scielzo C, Simonetti G, Ten Hacken E, Apollonio B, Ghia P, et al.
Leukemia
. 2012 Oct;
27(3):534-40.
PMID: 23041721
Xenotransplantation of human tumor cells into immunodeficient mice has been a powerful preclinical tool in several hematological malignancies, with the notable exception of chronic lymphocytic leukemia (CLL). For several decades,...
5.
Scielzo C, Apollonio B, Scarfo L, Janus A, Muzio M, Ten Hacken E, et al.
Leukemia
. 2011 Jun;
25(11):1760-7.
PMID: 21709686
Malignant B lymphocytes from chronic lymphocytic leukemia (CLL) patients maintain the capacity to respond to CD40 ligation, among other microenvironmental stimuli. In this study, we show that (i) leukemic CLL...
6.
Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J, et al.
Lancet
. 2010 Oct;
376(9747):1164-74.
PMID: 20888994
Background: On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine...
7.
Santoro A, Pressiani T, Citterio G, Donadoni G, Pozzi F, Rimassa L, et al.
Br J Cancer
. 2010 Aug;
103(6):837-44.
PMID: 20717115
Background: Hepatocellular carcinoma (HCC) is a highly vascularised and poor-prognosis tumour. NGR-hTNF is a vascular-targeting agent consisting of human tumour necrosis factor-alpha fused to the tumour-homing peptide NGR, which is...
8.
Bertilaccio M, Scielzo C, Muzio M, Caligaris-Cappio F
Best Pract Res Clin Haematol
. 2010 Jul;
23(1):21-32.
PMID: 20620968
Chronic lymphocytic leukaemia (CLL) is characterised by accumulation of CD5(+) monoclonal B cells in primary and secondary lymphoid tissues. Genetic defects and stimuli originating from the microenvironment concur to the...
9.
10.
Poggi A, Catellani S, Bruzzone A, Caligaris-Cappio F, Gobbi M, Zocchi M
Leukemia
. 2008 Feb;
22(5):980-8.
PMID: 18288129
In this study, we analysed 30 patients with B-cell chronic lymphocytic leukaemia (CLL), compared with 10 healthy donors, for the expression and function of the leukocyte-associated Ig-like receptor-1 (LAIR-1). LAIR-1...